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Meta-analysisAging is considered as one of the main factors promoting the risk for Parkinson's disease (PD), and common
mechanisms of dopamine neuron degeneration in aging and PD have been proposed in recent years. Here, we
use a statistical meta-analysis of human brain transcriptomics data to investigate potential mechanistic relation-
ships between adult brain aging and PD pathogenesis at the pathway and network level. The analyses identify
statistically signiﬁcant shared pathway and network alterations in aging and PD and an enrichment in
PD-associated sequence variants from genome-wide association studies among the jointly deregulated genes.
We ﬁnd robust discriminative patterns for groups of functionally related genes with potential applications as
combined risk biomarkers to detect aging- and PD-linked oxidative stress, e.g., a consistent over-expression of
metallothioneinsmatchingwith ﬁndings in previous independent studies. Interestingly, analyzing the regulatory
network and mouse knockout expression data for NR4A2, a transcription factor previously associated with rare
mutations in PD and here found as the most signiﬁcantly under-expressed gene in PD among the jointly altered
genes, suggests that aging-related NR4A2 expression changes may increase PD risk via downstream effects similar
to disease-linked mutations and to expression changes in sporadic PD. Overall, the analyses suggest mechanistic
explanations for the age-dependence of PD risk and reveal signiﬁcant and robust shared process alterations with
potential applications in biomarker development for pre-symptomatic risk assessment or early stage diagnosis.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Parkinson's disease (PD) is one of themost common neurodegener-
ative disorders and a disease-modifying therapy is still not available.
With an average age of onset of 60 years and a risk of developing
sporadic PD known to increase signiﬁcantly with age, the disease has
been linked with aging by several studies (Bender et al., 2006; Collier
et al., 2011; Frey et al., 2004; Hindle, 2010; Levy, 2007; Kaasinen and
Rinne, 2002; Naoi and Maruyama, 1999). Previous hypotheses have
suggested a combination of age-related neuronal attrition and environ-
mental factors as a major cause for sporadic PD (Calne et al., 1986) or
that aging may inﬂuence the clinical progression of the disease (Levy,
2007). More recently, PD has also been proposed to represent a form
of premature or accelerated aging (Collier et al., 2011). Independent of
the type and extent of association between aging and PD pathogenesis,
various shared molecular hallmarks have been observed, including a
gradual decline in dopamine synthesis (Scatton et al., 1983; Ota et al.,
2006), reduced striatal density of the type 2 vesicularmonoamine trans-
porter (Frey et al., 2004) and increased levels of deleted mitochondrialems Biomedicine, 7, avenue des
Fax: +352 466644 6949.
ect.com).
. This is an open access article underDNA (Bender et al., 2006). These common features suggest that
a more comprehensive investigation of shared/interlinked cellular
process changes in aging and PD could provide new insights on the
disease etiology and progression and facilitate the discovery of pre-
symptomatic risk biomarkers for PD or general neurodegeneration.
In recent years, large-scale transcriptomic measurements from re-
search studies on brain aging and complex neurodegenerative disorders
have been made available in public data repositories (Barrett et al.,
2009; Kang et al., 2011; Jones et al., 2009; Lein et al., 2006). Although
these data sources have been analyzed individually (Kang et al., 2011;
Johnson et al., 2009; Zhang et al., 2005; Lesnick et al., 2007; Kumar
et al., 2013), the potential for a joint pathway- and network-analysis
of high-throughput gene expression data for aging and PD has not yet
been exploited, despite PD being regarded as one of the prime examples
of an age-related disease (Hindle, 2010).
Here, we investigate relations between brain transcriptome changes
in PD patients (as compared to age-matched, non-demented control
subjects) and transcriptome changes associated with adult brain aging
in a separate group of unaffected individuals, exploiting new cross-
study data integration, pathway and network analysis methods. Specif-
ically, we ﬁrst apply a recent statistical meta-analysis approach (Marot
et al., 2009) to 8 public microarray gene expression data sets (Zhang
et al., 2005; Lesnick et al., 2007; Moran et al., 2006; Simunovic et al.,
2009; Zheng et al., 2010), using post mortem samples from themidbrainthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
2 E. Glaab, R. Schneider / Neurobiology of Disease 74 (2015) 1–13substantia nigra region in patients and age- and gender-matched con-
trols, and then compare the differentially expressed genes in PD from
the meta-analysis to genes associated with adult brain aging. These
aging-associated genes are derived from a statistical analysis of post
mortem microarray samples from the Human Brain Transcriptome
(HBT) project (Kang et al., 2011), by determining signiﬁcant brain
gene expression changes across different age groups during adulthood.
By integrating these data to identify shared and associated gene expres-
sion alterations during natural brain aging and in PD, we aim at two
main goals: (1) obtaining a more detailed molecular-level understand-
ing of how aging contributes to the risk for PD and (2) ﬁnding robust
shared alterations in PD and aging for further evaluation as candidate
early risk biomarkers for PD or general neurodegeneration. The poten-
tial of the jointly altered genes for biomarker applications is investigated
using public data to determine their expression in peripheral tissues, to
identify their previously reported PD/aging-linked peripheral changes
and to evaluate the speciﬁcity of their alterations in PD as compared
to Alzheimer's disease.
These analyses at the single-gene level are complemented by a sta-
tistical assessment of cellular processes changes, using our previously
developed pathway and network analysis method EnrichNet (Glaab
et al., 2012) to identify shared signiﬁcant pathway and sub-network de-
regulations in PD and aging. The transcription factors most relevant for
the regulation of these affected sub-networks are predicted using
an over-representation analysis for transcription factor binding sites
among the altered genes in PD/aging. Finally, to investigate possible re-
lations between genetic variations and transcriptome alterations linked
to PD/aging, we test the enrichment of PD-associated single-nucleotide
sequence variants (SNPs) from public genome-wide association studies
(GWAS) among the altered genes in PD/aging and report the genes
found signiﬁcant in both transcriptomics and GWAS analyses.
Materials and methods
Microarray data collection, pre-processing and differential expression
analysis
In order to exploit the synergies of the available transcriptomics data
for a joint analysis of PD pathogenesis and brain aging, we collected post
mortem samples in the substantia nigramidbrain region from public PD
case–control microarray data sets, as well as post mortem microarray
samples from the Human Brain Transcriptome (HBT) project for 3
adult age periods (20 to 40 years, 40 to 60 years, and 60 years onwards;
used to identify aging-associated changes in brain gene expression dur-
ing adulthood, see below).
For the meta-analysis of substantia nigra brain samples from PD
case–control studies, raw microarray data were obtained from 8 pub-
lished data sets (Zhang et al., 2005; Lesnick et al., 2007; Moran et al.,
2006; Simunovic et al., 2009; Zheng et al., 2010). Importantly, the
samples were already age- and gender-matched to prevent biases in
downstream analyses. All microarray data sets were pre-processed
using the GC-RMA procedure for background correction, normalization
and probe replicate summarization (Wu et al., 2004), and only samples
from the substantia nigra brain regionwere retained for further analysis.
Since platform-speciﬁc biases can lead to artifacts when directly inte-
grating microarray data from different studies via cross-study normali-
zation methods, we instead used a meta-analysis to integrate statistical
results obtained on the individual data sets. First, differential expression
statisticswere computed on each data set separately using the empirical
Bayes moderated t-statistic (Smyth, 2004), and then the p-value signif-
icance scores were combined via the weighted meta-analysis approach
by Marot et al. (2009). In contrast to the commonly used unweighted
Fisher method for p-value combination, this approach involves data
set-speciﬁc weights reﬂecting the relative number of samples collected
in each study. The obtained meta-analysis p-values were adjusted for
multiple hypothesis testing using the approach by Benjamini andHochberg (1995) and a false discovery rate (FDR) threshold of 0.05 to
determine the ﬁnal gene selection. Since two of the microarray data
sets were derived using laser-capture microdissection (LCM), we con-
ﬁrmed the consistency between LCMand non-LCMdata by determining
the Spearman correlation between the median fold changes across
the LCM- and the non-LCM data sets for the genes considered in this
study (Spearman's rho = 0.634) and the signiﬁcance of the linear
regression ﬁt between these two data series (p= 2.19E−09).
For the aging-related microarray data from the Human Brain Tran-
scriptome project (Kang et al., 2011) (HBT), all samples covering the 3
main adult age periods 20 to 40 years, 40 to 60 years and 60 years
onwards were collected in order to identify differentially expressed
genes across these age groups. Importantly, asmentioned in the original
publication for the HBT project, none of the individuals included in this
study suffered from any known neurological or psychiatric disorder,
severe head injuries or signs of neurodegeneration (Kang et al., 2011).
The signiﬁcance of differential expression across the age groups was
computed using a dedicated multiclass-analysis method designed for
microarray data (Tusher et al., 2001). We chose this speciﬁc approach
in order to identify increases or decreases in gene expression variance
related to aging in addition to positive or negative correlations with
aging (the correlation with aging is additionally reported in Tables 1
and 2, and for the full-length gene ranking table in the Supplementary
Material). Finally, the heat map visualizations in Figs. 1, 2 and 3 were
generated using a Pearson correlation hierarchical clustering (i.e., the
distance metric is 1-correlation; larger versions of these heat maps in-
cluding the gene names, as well as heat maps for a Euclidean distance
metric and additional sample clustering are provided in the Supplemen-
tary Material, see Fig. S1–S8).
Network-based enrichment analysis of PD and aging transcriptomics data
To analyze associations between the deregulated genes in PD/aging
and cellular pathways and exploit additional information from public
molecular interaction data, we used our algorithm EnrichNet for
network-based gene/protein set enrichment analysis (see Glaab
et al., 2012 for a detailed description and the publicly available
web-application www.enrichnet.org). Brieﬂy, EnrichNet consists of
a 3-step procedure: First, a gene or protein set of interest (the target
gene set) as well as gene/protein sets representing cellular pathways
from public databases (the reference gene sets) are mapped onto a
genome-scale protein–protein interaction network. Next, a deterministic
procedure for simulating randomwalks in a network (the RandomWalk
with Restart algorithm Tong et al., 2008) is applied to score the network
distances and multiplicity of interactions between the target and refer-
ence gene/protein sets. In order to obtain ﬁnal association scores for the
pathway reference sets, the combined interconnectivity/distance scores
are compared to a background score distribution using the XD-statistic
(Olmea et al., 1999; Glaab et al., 2012) (larger XD-scores reﬂect stronger
associations, and the algorithm determines an XD-score signiﬁcance
threshold corresponding to a false-discovery rate of 0.05).
Here, in order to identify and score network associations of the
deregulated genes in aging and PD with known cellular pathways, we
applied EnrichNet on a target gene set given by the intersection of the
signiﬁcant genes from the differential expression analyses of the aging
and PD transcriptome data (FDR b 0.05, see above). The pathway-
representing reference gene sets were obtained from the public da-
tabases Gene Ontology (Ashburner et al., 2000), KEGG (Kanehisa
and Goto, 2000), WikiPathways (Pico et al., 2008) and Reactome
(Joshi-Tope et al., 2005). To assemble the genome-scale protein–pro-
tein interaction network only experimentally veriﬁed, direct physi-
cal interactions from public data repositories including tissue-
speciﬁcity annotations (Bossi and Lehner, nd.) were used. In addition
to the network association scores obtained from the graph-based
statistic, we also performed a conventional over-representation
analysis, scoring the signiﬁcance of the overlap between target and
Table 1
Signiﬁcantly differentially expressed genes in both Parkinson's disease and adult brain aging (Top 50, FDR b 0.05, see Supplementary Material for the complete list).
CorrelationDeregulation in PDGene descriptionGene symbol
with agingsamples (Z–score)(HGNC)
–7.43 –0.53
–7.13 –0.31
–7.06 –0.53
6.86 0.2
6.32 0.42
–6.3 –0.39
–6.28 –0.57
6.16 –0.39
–6.13 –0.43
–6.09 –0.54
–6.06 –0.51
–6.05 –0.47
6.01 –0.54
–5.97 –0.41
–5.8 –0.58
–5.51 –0.35
–5.4 –0.2
–5.46 –0.3
5.43 –0.41
5.39 –0.28
–5.3 –0.6
–5.14 0.32
–5.03 0.26
–4.99 –0.45
–4.93 –0.34
–4.92 –0.5
–4.86 0.48
4.68 –0.48
4.57 –0.25
4.55 0.34
–4.51 0.38
4.42 0.27
–4.37 –0.58
–4.36 –0.54
4.33 0.38
4.31 0.57
4.29 0.4
–4.22 –0.62
–4.2 –0.44
4.16 –0.58
4.15 –0.52
4.13 –0.37
4.09 0.38
4.09 –0.42
4.05 –0.41
–3.97 –0.59
3.95 0.01
–3.95 –0.47
–3.93 –0.33
NR4A2 nuclear receptor subfamily4, group A, member 2
NAP1L2 nucleosome assembly protein 1–like 2
PEG10 paternally expressed 10
MCM7 minichromosome maintenance complex component 7
CLK1 CDC–like kinase 1
TNFRSF21 tumor necrosis factor receptor superfamily, member 21
STAM signal transducing adaptor molecule 1
KCNJ2 potassium inwardly–rectifying channel, subfamily J, member2
SLIT1 slithomolog1 (Drosophila)
CDH8 cadherin 8, type 2
GRIA1 glutamate receptor, ionotropic, AMPA1
SERINC3 serinein corporator 3
KAZ kazrin
MAP3K9 mitogen–activated protein kinase kinase kinase 9
MYT1L myelin transcription factor 1–like
C12orf43 chromosome 12 open reading frame 43
PLD3 phospholipase D family, member 3
BSN bassoon (presynaptic cytomatrix protein)
MORC2 MORC family CW–type zinc finger 2
SUN2 Sad 1 and UNC 84 domain containing 2
CACNA1G voltage–dependent calcium channel, Ttype, alpha 1G subunit
ATP6V1F ATPase, H+ transporting, lysosomal 14kDa, V1subunitF
NHLH2 nescient helix loop helix 2
FAM49A family with sequence similarity 49, member A
AAK1 AP2 associated kinase 1
LARP1 La ribonucleoprotein domain family, member 1
ZNF365 zinc finger protein 365
CREBBP CREB binding protein
ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10
SDCCAG3 serologically defined colon cancer antigen 3
NDUFB2 NADH dehydrogenase (ubiquinone) 1beta subcomplex, 2
MT1H metallothionein 1H
AFF2 AF4/FMR2 family, member 2
CCDC92 coiled–coil domain containing 92
CDKN1A cyclin–dependent kinase inhibitor 1A (p21, Cip1)
MT1G metallothionein 1G
PHF10 PHD finger protein 10
FKBP11 FK506 binding protein 11, 19 kDa
CAMTA1 calmodulin binding transcription activator 1
ACSL1 acyl–CoA synthetase long–chain family member 1
DUSP7 dual specificity phosphatase 7
INF2 inverted form in, FH2 and WH2 domain containing
ASCL1 achaete–scute complex homolog1 (Drosophila)
NPAS2 neuronal PAS domain protein 2
PLEKHM1 pleckstrin homology domain containing, familyM member 1
CALB1 calbindin 1,28kDa
PHB prohibitin
LMF1 lipase maturation factor 1
BTBD3 BTB (POZ) domain containing 3
CLIC2 chloride intracellular channel 2 3.92 0.5
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corrections (Benjamini and Hochberg, 1995, both scores are provid-
ed in Table 3). Importantly, the network association score and the
over-representation score may reﬂect different types of functional
associations; hence, for both types of approaches, we report the
identiﬁed pathways with estimated false-discovery rate below 0.05
(see Table 3 and Supplementary Material).SNP over-representation analysis
To identify genes with PD-associated SNPs from public genome-
wide association studies (GWAS) coinciding with the signiﬁcantly al-
tered genes in PD and aging obtained from the analyses described
above, we collected SNPs with phenotype label “Parkinson's disease”
from the Ensembl Variation database (Chen et al., 2010). These SNPs
Table 2
Molecular functions of deregulated genes in aging and PD.
CorrelationDeregulationGeneGeneFunction
within PD samplesdescriptionsymbol
(Z–score) aging
–4.51 0.38
Mitochondrial 3.95 0.01
3.01 –0.58
2.72 0.58
2.57 0.61
3.6 0.39
–3.55 –0.49
2.92 0.19
4.09 0.38
Neuron –2.63 –0.35
differentiation –2.8 –0.33
–3.43 –0.38
–7.43 –0.53
–6.13 –0.43
2.92 0.19
–3.92 –0.49
Apoptosis –3.12 –0.28
–7.06 –0.53
3.32 0.53
–6.3 –0.39
–4.37 –0.58
Cognition –3.55 –0.49
(learning, 2.92 0.19
memory) –3.97 –0.59
–6.06 –0.51
3.6 0.39
Inflammatory 2.68 0.35
response –3.02 –0.53
–7.43 –0.53
2.67 0.01
–5.3 –0.6
–3.17 –0.43
6.16 –0.39
Ionchannel –3.69 –0.41
3.92 0.5
–6.06 –0.51
–3.49 –0.28
3.01 –0.27
Lysosomal 3.32 0.53
–2.97 –0.37
4.31 0.57
Metalion 4.42 0.27
homeostasis
NDUFB2 NADH dehydrogenase (ubiquinone)
1 beta subcomplex, 2, 8kDa
PHB prohibitin
ELAVL1 embryonic lethal, abnormal vision, Drosophila–like 1
PCK1 phosphoenolpyruvate carboxykinase 1 (soluble)
HSD17B14 hydroxysteroid (17–beta) dehydrogenase 14
CEBPB CCAAT/enhancer binding protein(C/EBP), beta
EPHB2 EPH receptor B2
RASGRF1 Ras protein–specific guanin enucleotide–releasing factor 1
ASCL1 achaete–scute complex homolog1 (Drosophila)
CXCL12 chemokine (C–X–Cmotif) ligand 12
CNTNAP2 contactin associated protein–like 2
EFNB3 ephrin–B3
NR4A2 nuclear receptor subfamily 4, groupA, member 2
SLIT1 slit homolog1 (Drosophila)
RASGRF1 Ras protein–specific guanine nucleotide–releasing factor 1
EIF2AK2 eukaryotic translation initiation factor 2–alpha kinase 2
GGCT gamma–glutamylcyclotransferase
PEG10 paternally expressed 10
SRGN serglycin
TNFRSF21 tumor necrosis factor receptor superfamily, member 21
AFF2 AF4/FMR2 family, member 2
EPHB2 EPH receptor B2
RASGRF1 Ras protein–specific guanine nucleotide–releasing factor 1
CALB1 calbindin 1, 28kDa
GRIA1 glutamate receptor, ionotropic, AMPA 1
CEBPB CCAAT/enhancer binding protein (C/EBP), beta
ADORA3 adenosine A3 receptor
ATRN attractin
NR4A2 nuclear receptor subfamily 4, group A, member 2
C3AR1 complement component 3a receptor 1
CACNA1G calciumchannel,voltage–dependent,
Ttype,alpha1Gsubunit
CACNG3 calciumchannel,voltage–dependent,gammasubunit3
KCNJ2 potassiuminwardly–rectifyingchannel,
subfamily J, member 2
KCNB1 potassium voltage–gated channel
Shab–related subfamily, member 1
CLIC2 chloride intracellular channel 2
GRIA1 glutamate receptor, ionotropic, AMPA 1
P2RX5 purinergic receptor P2X, ligand–gated ion channel, 5
NPC1 Niemann–Pick disease, type C1
SRGN serglycin
SMPD1 sphingomyelin phosphodiesterase1, acid lysosomal
MT1G metallothionein 1G
MT1H metallothionein 1H
AKR1C3 aldo–ketoreductase family1, member C3 3.49 0.45
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score: (1) SNPs with genome-wide signiﬁcance (deﬁned as p b 10E-08)
and (2) suggestive SNPs (deﬁned as p b 0.001). The over-representation
of genes containing SNPs from group 1 and 2 among the jointly
deregulated genes in aging and PD were both scored using the one-
tailed Fisher exact test.
Results and discussion
Shared signiﬁcant deregulations of individual genes in Parkinson's disease
and brain aging
When determining the intersection between the differentially
expressed transcripts/genes obtained from the PD meta-analysis
with those from the aging data analysis, 120 signiﬁcant transcripts(FDR b 0.05) mapping to unique shared genes were identiﬁed (the
top 50 sorted by absolute Z-score across the 8 PD microarray data sets
are listed in Table 1; the complete list is provided in the Supplementary
Material). Heat map visualizations showing the expression levels of the
120 genes in PD samples vs. controls and in different age groups for un-
affected individuals are displayed in Figs. 1 and 2 (Pearson correlation
hierarchical clustering was applied, see Supplementary Material for
alternative clustering approaches).
Apart from these gene-level clustering, an additional hierarchical
clustering was applied to the samples (see Fig. 3) to identify potential
grouping patterns among them and see whether the top-level clusters
show an association with the disease and control sample groups. How-
ever, no such relation was identiﬁed, which may be explained by three
possible reasons: (1) biological grouping patterns among the samples
exist which are unrelated to the disease/control-group differences of
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Fig. 1. Heat map for the expression levels of the 120 transcripts signiﬁcantly altered in aging and PD in the data set by Moran et al. (2006), comparing brain samples from the substantia
nigra in Parkinson's patients (red) against controls (blue; see also the heat map in Fig. 2 showing the same transcripts across different age groups). The plot uses a Pearson correlation
hierarchical clustering for the genes (see dendrogram on the left and black horizontal line, indicating the top-level cluster separation). A larger version of thismap and an alternative clus-
tering with the Euclidean distance metric for both genes and samples including all gene labels is provided in the Supplementary Material.
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Fig. 2. Heat map for the expression levels of the 120 transcripts signiﬁcantly altered in aging and PD in the Human Brain Transcriptome data set (Kang et al., 2011), comparing brain samples
across three different age groups (20–40 years, 40–60 years and 60+ years; see also Fig. 1 showing the same transcripts in PD brain samples vs. controls). The plot uses a Pearson correlation
hierarchical clustering (see dendrogram on the left and black horizontal lines, indicating the top-level cluster separations). A larger version of this map and an alternative clustering with the
Euclidean distance metric for both genes and samples including all gene labels is provided in the Supplementary Material (details on the generation of the map are described in the Methods
section).
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Fig. 3. Heat map for the expression levels of the 120 transcripts signiﬁcantly deregulated in aging and PD in the data set by (Moran et al., 2006), comparing brain samples from the
substantia nigra in Parkinson's patients (red) against controls (blue). A Pearson correlation distance metric was used to obtain the clustering for both rows and samples (the retained
top-level cluster separation from Fig. 1 is indicated by the black horizontal line). The identiﬁed sample clusters do not coincide with the two known sample conditions (see color legend
above). A larger version of this map and an alternative clustering with the Euclidean distance metric including all gene labels is provided in the Supplementary Material.
6 E. Glaab, R. Schneider / Neurobiology of Disease 74 (2015) 1–13interest (e.g., reﬂecting differences in diet, lifestyle, etc.); (2) the implic-
it assumption of the clustering algorithm that a hierarchical structure
exists among the samples is not fulﬁlled (while genes can often be -
clustered into hierarchical categories of functionally similar genes,
for samples from a case–control study with no family relationshipsbetween the participants a hierarchical structure cannot be expected a
priori, and the differences between PD samples and controls may be
gradual and form a continuous spectrum rather than segregating into
discrete clusters); and (3) the complexity and heterogeneity of the
high-dimensional data prevents the unsupervised clustering approach
Table 3
Signiﬁcant network associations of deregulated genes in aging and PD with Gene Ontology biological processes.
GO term Network association score
(XD-score)
Signiﬁcance of overlap q-value
(Fisher's exact test)
Mapped pathway size Overlap size
Dopamine metabolic process (GO:0042417) 1.61 0.38 14 4
Synaptic vesicle endocytosis (GO:0048488) 1.47 0.46 10 3
Positive regulation of synaptic transmission (GO:0050806) 1.47 0.46 10 3
Synaptic transmission, dopaminergic (GO:0001963) 1.46 0.60 13 3
Regulation of long-term neuronal synaptic plasticity (GO:0048169) 1.38 0.19 21 6
Positive regulation of endocytosis (GO:0045807) 1.36 0.33 13 4
Phosphatidylinositol metabolic process (GO:0046488) 1.27 0.16 19 6
Synaptic transmission (GO:0007268) 0.29 0.00067 300 38
7E. Glaab, R. Schneider / Neurobiology of Disease 74 (2015) 1–13from capturing speciﬁcally the clinically relevant patterns of interest
and supervised analysis techniques which make use of the available
sample class labels are required instead. In the remainder of the manu-
script, we therefore focus on supervised analysis methods for gene
ranking, pathway and network analysis, whichdonot dependonhierar-
chical structure assumptions. These methods also enable an assessment
of the statistical signiﬁcance, which is used to compare only the signiﬁ-
cant ﬁndings against the literature.
Aﬁrst general comparison of the direction of gene alterations in both
data sources shows that for themajority of genes, a down-regulation in
the PD cases coincides with a negative correlation with aging, and
correspondingly, a positive correlation with aging is observed more
frequently for genes up-regulated in PD (with signiﬁcant Pearson and
Spearman correlations between the PD-related Z-scores and the corre-
lations with aging of 0.43 and 0.36, respectively; permutation-based
p-value b 0.001 in both cases).
Four of the shared signiﬁcant genes, NR4A2, CALB1, GRIA1 andMAPT,
have been associated previously with PD and aging in independent
studies. Among these, NR4A2 (also known as NURR1) stands out as the
most signiﬁcantly differentially expressed gene (Z-score:−7.43) and
for a high negative correlation with adult brain aging (−0.53, see box
plot in Fig. 4 and statistics in Table 1). We therefore focus on the discus-
sion of NR4A2 and the literature ﬁndings relating to the other three
genes are summarized in Table S9.
NR4A2 encodes a brain-speciﬁc transcription factor belonging to the
nuclear receptor superfamily and controlling the expression of genes
involved in the maintenance of the nervous system and dopamine
metabolism (Sacchetti et al., 2006). Mutations and polymorphisms in
this gene in familial cases of PD have been reported in multiple studies
(Le et al., 2003; Xu et al., 2002; Zheng et al., 2003; Grimes et al., 2006;
Liu et al., nd.; Sleiman et al., 2009), but these sequence variants onlyFig. 4. (a) Box plot showing themedian (bold horizontal line), interquartile range (box) and tota
and all brain regions in the HBT data set. (b) Box plot showing the median (bold horizontal lin
values across closely age-matched PD patients and healthy controls in the data set by Moran
expression alterations shown in a and b are statistically signiﬁcant (FDR b 0.05).occur rarely and dedicated screening for them was unsuccessful in
other cohorts (Zimprich et al., 2003; Nichols et al., 2004; Tan et al.,
2004). PD-like molecular phenotypes were also observed in homozy-
gous NR4A2-deﬁcient mice, with a region-speciﬁc lack of dopaminergic
neurons in the substantia nigra and ventrotegmental area (Le et al.,
1999a). Moreover, in heterozygous knockout mice, reduced brain
dopamine levels (Zetterström et al., 1997) and a signiﬁcant decrease
in locomotor activities as compared to age-matched wild-type mice
have been reported (Jiang et al., 2005). A relation between NR4A2 and
natural human aging (independent of PD pathogenesis) had been
proposed in a previous study showing that the number of NR4A2-
immunoreactive nigral neurons is signiﬁcantly reduced in middle-
aged (23.13%) and aged (46.33%) individuals as compared to young
subjects (Chu et al., 2002), in agreement with the results shown here.
Interestingly, reduced NR4A2 expression in heterozygous knockout
mice has also been shown to increase the vulnerability of dopaminergic
neurons to the neurotoxin MPTP, which induces Parkinsonism-like
phenotypes, suggesting a neuroprotective role for the gene (Le et al.,
1999b). More recently, down-regulation of NR4A2 was shown to
transcriptionally increase the expression of alpha-synuclein (Yang and
Latchman, 2008), a gene for whichmutations, duplications and triplica-
tions have been linked causally with PD and whose protein aggregation
is considered as one of the main molecular hallmarks of PD (Ibanez
et al., 2004; Chartier-Harlin et al., 2004; Fuchs et al., 2007).
Considering these observations in mice and humans in combination
with the highly signiﬁcant down-regulation of NR4A2 in PD and during
natural aging observed here, we hypothesize that an age-related decline
of NR4A2 brain expression levels in healthy individuals may increase the
risk for developing PD independent of the presence of mutations or
polymorphisms in this gene. A network analysis of the downstream ef-
fects ofNR4A2 under-expression in PDusingmanually curated regulatoryl range (whiskers) of normalizedNR4A2 expression levels across three different age groups
e), interquartile range (box) and total range (whiskers) of normalized NR4A2 expression
et al. (Moran et al., 2006) (median age PD cases: 81, median age control cases: 77). Both
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signiﬁcant down-regulation of direct target genes involved in dopamine
metabolism, matching with previous observations for NR4A2mutations
and knockout mice (see downstream network in Fig. S9). Moreover,
when comparing genes differentially expressed in midbrain dopaminer-
gic neurons of NR4A2 knockout mice as opposed to wildtype mice
(Kadkhodaei et al., 2013) against the signiﬁcantly altered genes in PD
from the meta-analysis of human brain samples, 45 shared signiﬁcant
genes are found (see Table S4), including the known direct NR4A2
targets TH and SLC18A2, which are markedly under-expressed in
both data sets. In total, 32 genes display shared signiﬁcant down-
regulation in the knockout model and the PD meta-analysis, one
gene, DDX3Y, is jointly up-regulated and 13 genes show opposite
alterations, potentially resulting from more complex multifactorial
and indirect regulatory mechanisms (see Table S4). Interestingly,
the jointly down-regulated genes contain the mitochondrial com-
plex I genes NDUFB2 and NDUFB8, suggesting a possible mechanistic
link between NR4A2 dysregulation andmitochondrial dysfunction in
Parkinson's disease for further study (NDUFB2 expression in the brain is
also altered during adult aging in the HBT data set, displaying an up-
regulation with increasing age).
Next, in order to narrow down potential upstream regulatory causes
for the observed age-dependent down-regulation of NR4A2, a networkFig. 5.Upstream regulatory network for NR4A2 revealing down-regulated genes in aging associ
is proportional to the absolute Z-score of differential expression). A more comprehensive int
different color-overlays for deregulated genes in aging and in PD (http://minerva.uni.lu/MapVanalysis was applied to NR4A2 upstream regulators. This analysis
identiﬁed a signiﬁcant down-regulation of CREB-dependent gene tran-
scription with increasing age as putative upstream cause for the age-
associated decline in NR4A2 expression levels (see the network visuali-
zation shown in Fig. 5). Since CREB activation mediates mitochondrial
gene expression and survival in response to mitochondrial dysfunction
(Arnould et al., 2002; Lee et al., 2005), the down-regulation of CREB
regulator genes with increasing age also matches with observed age-
associated alterations in mitochondrial processes found in the analysis
of gene groups with shared molecular functions (see corresponding
section below).
In summary, the 120 shared deregulated genes in aging and PD
display signiﬁcant correlation in terms of the direction of their expres-
sion changes (with a majority of up- and down-regulation patterns
occurring jointly in higher age groups and in PD samples vs. controls)
and include four genes that have been implicated in PD and aging in
multiple independent studies (NR4A2, MAPT, GRIA1 and CALB1). For
the observed under-expression of NR4A2, the combination of tran-
scriptome network analyses, mouse knockout data analysis and previ-
ous ﬁndings from the literature provide details on possible upstream
causes and downstream effects, suggesting in particular that NR4A2
has a regulatory inﬂuence on the expression levels of alpha-synuclein
and mitochondrial complex I genes.atedwith regulation of CREB-dependent gene transcription (blue nodes, the color darkness
eractive cellular pathway map for Parkinson's disease map can be explored online using
iewer/map?id=pdmap-ageing).
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for biomarker applications
Apart from using the identiﬁed jointly deregulated genes in PD and
aging to analyze the age-dependence of PD risk at the molecular level,
these genes may also serve as candidates for developing new risk
biomarkers for PD or general neurodegeneration. The rationale is that
the jointly deregulated genes are more likely to reﬂect age-dependent
contributions to the disease risk than genes altered only in PD, and
their expression levels could therefore mark an increased risk already
before the onset of motor symptoms. Future validation studies will
however ﬁrst need to identify peripheral surrogate markers to assess
gene deregulations in the brain indirectly, e.g., by screening for correlat-
ed gene or protein expression levels in cerebrospinal ﬂuid, blood or
saliva. Previously, similar approaches have been applied successfully
to other neurological disorders, e.g., a blood biomarker for schizophre-
nia has been derived from a comparative gene expression analysis of
brain and blood samples (Glatt et al., 2005). We have therefore used
tissue-speciﬁc gene expression data from the public GNF Gene Expres-
sion Atlas (Su et al., 2004) to provide a tabular overview of the extent
to which the 120 jointly altered genes in PD/aging are expressed in
peripheral blood and across different non-brain tissues as compared to
brain tissues (see Table S5). For the majority of genes, the median
expression in peripheral tissues is similar or higher in relation to
the median expression in the brain. Table S5 also highlights the genes/
proteins for which altered activities in PD or aging have been reported
previously in peripheral body ﬂuids and tissues, including NR4A2 and
themetallothioneinsMT1H andMT1G (see also the gene group analysis
in the following section).
Moreover, to examine the speciﬁcity of the jointly altered genes for
PD as compared to a different neurodegenerative disorder, the same
normalization procedure and test statistic was applied to determine
the genes' differential expression in Alzheimer's disease (AD) brain
transcriptomics data, covering 387 annotated AD samples and 300
controls (Zhang et al., 2013). Although the comparability of the PD
and AD transcriptomics data is necessarily limited due to differences
in the brain regions considered as the main sites affected (substantia
nigra in PD vs. hippocampus in AD) and the lack of a matching between
progression stages in the two diseases, 95 of the 120 jointly altered
genes in PD/aging were also signiﬁcantly differentially expressed in
AD, and 85 of these altered in the same direction (up/down) as in PD
(corresponding to an overall matching of 70.8%, see Table S6). While
the shared signiﬁcant genes in PD, AD and aging provide possible
candidates for general biomarkers of neurodegeneration, the genes
with diverse alteration direction in PD as compared to AD and aging
(e.g., NPAS2 and EXT1) could be of interest for the development of
PD-speciﬁc markers. However, in order to obtain robust biomarker
models, further validation of these candidate genes/proteins and their
activity proﬁles in peripheral tissues will be required on large-scale in-
dependent cohorts, including the investigation and testing of multifac-
torial marker models.
Joint PD/aging-related expression changes in groups of genes with shared
molecular functions
In order to facilitate the biological interpretation of newly identiﬁed
genes with joint alterations in aging and PD, we have grouped them ac-
cording to their shared molecular function annotations (see Table 2). A
further goal was to determine whether the intersection between late-
stage PD-deregulated genes and aging-associated genes would be
enriched in cellular processes implicated in the early/prodromal-stage
and progression of the disease rather than mainly representing late-
stage downstream effects. Since aging is considered as a major risk-
promoting factor for PD, joint aging/PD-associatedmolecular alterations
would be expected to occur already in the early and presymptomatic
stages of PD. Thus, interlinking the joint transcriptome changes withpathway alterations implicated in the initial phases of PD could help
to reduce the need for scarcely available prodromal-stage data in the
search for early stage diagnostic biomarkers.
Overall, the identiﬁed processes affected by joint PD/aging expres-
sion changes largely matchwith cellular processes previously proposed
to be linked with the early phases of PD pathogenesis, including mi-
tochondrial and lysosomal processes, apoptosis and processes asso-
ciated with neuron differentiation and inﬂammation (McGeer and
McGeer, 2004; Pan et al., 2008; Shadrina et al., 2010). The observed
mitochondrial alterations are in line with previous discoveries of
disease-causing mutations in familial cases of PD, affecting the mito-
chondrial genes DJ1, PINK1, PARK2 and HTRA2 and supporting the hy-
pothesis of an involvement of mitochondrial dysfunction in the early
stages of idiopathic PD (Abou-Sleiman et al., 2006; Büeler, 2009). More-
over, pesticides and neurotoxins acting atmitochondrial complex I have
been described to induce Parkinsonism-like symptoms (Sherer et al.,
2007). In our study, we observe signiﬁcant alterations in the gene for
complex I subunitNDUFB2 in both aging and PD. Among the 45 complex
I subunits, NDUFB2 functions as an NADH dehydrogenase and oxidore-
ductase and is involved in the transfer of electrons fromNADH to the re-
spiratory chain.
Similar to mitochondrial dysfunction, defects in the lysosome/
autophagy pathway (ALP) have also been considered as possible causes
of PD and other neurodegenerative diseases (see (Pan et al., 2008) for
example). Interestingly, among the lysosomal genes found jointly
altered in PD and aging here, the gene SMPD1 can harbor different
rare variants, which have recently been proposed as risk factors for PD
in different studies (Gan-Or et al., 2013; Foo et al., 2013).
A causal role of inﬂammation in PD is more controversially
discussed. While inﬂammatory responses are observed in many dis-
eases and often regarded as a purely secondary effect, more recently,
neuro-inﬂammatory processes have been investigated as possible
causative or contributing factors in PD. For example, microglial over-
activation is thought to result in the loss of dopaminergic neurons in
PD patients (Qian et al., 2010) and large numbers of human leukocyte
antigens (HLA-DR) and CD11b-positive microglia have been detected
in the substantia nigra brain region in patients (McGeer et al., 1988).
The down-regulated transcription factor NR4A2, discussed in detail
above, has been shown to act as a repressor of genes encoding pro-
inﬂammatory neurotoxic factors in microglia and astrocytes, protecting
dopaminergic neurons from inﬂammation-induced death (Saijo et al.,
2009). A further inﬂammation-associated regulator detected as signiﬁ-
cantly under-expressed in PD and with increasing age is attractin
(ATRN), involved in the initial immune cell clustering during the inﬂam-
matory response. Attractin overexpression has been shown to protect
mitochondrial function in animal studies with Parkinsonism-inducing
toxins, and an aging-dependent decrease in ATRN expression has also
been observed in mice (Paz et al., 2007).
While most signiﬁcantly deregulated processes in aging and PD pre-
sented in Table 2 cover both up-and down-regulated genes, a consistent
joint up-regulation in PD and positive correlation with aging was found
for a group of three genes involved in metal ion homeostasis. They in-
clude two metallothioneins (MTs),MT1G and MT1H, encoding metal-
binding proteins known to be involved in the cellular response to
metal ion toxicity, oxidative stress and inﬂammation (Andrews, 2000).
MTs have been shown to prevent oxidative stress and attenuate apopto-
sis, and experiments on animal models suggest that MTs also promote
neuronal survival and regeneration in vivo (Sharma and Ebadi, 2011;
Ambjørn et al., 2008). Activation of MTs has also been proposed as a
strategy to inhibit neurodegenerative alpha-synucleinopathies like PD,
and MT activity proﬁles have been suggested as early stage markers
for neurodegeneration (Sharma and Ebadi, 2011). Apart from the
identiﬁed jointly deregulated MTs in PD and aging, we found further
MTs signiﬁcantly up-regulated in the PD transcriptomics samples
(MT1M,MT1F,MT1P2,MT1X,MT2A,MT3,MT4, as well as the transcrip-
tion factor MTF1 regulating MT expression), while no MT transcript
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MT over-expression as a robust multigene biomarker for PD or general
neurodegeneration. Support for an involvement of MTs in neurodegen-
eration was also obtained by the analysis of PD-associated GWAS data
(see corresponding section below).
Apart from investigating pre-deﬁned gene groups with shared func-
tional annotations, we also applied a differential co-expression analysis
(Watson, 2006) to identify new groups of co-expressed genes among
the jointly altered genes in PD and aging, whose co-expression pattern
changes in PD as compared to controls. However, no signiﬁcant co-
expression pattern identiﬁed on individual transcriptomics data
sets was found replicated across the data from other PD case–control
studies (only the metallothioneins MT1G and MT1H were consis-
tently co-expressed across different data sets, matching with the
observed up-regulation of the transcription factor MTF1 which co-
regulates their expression, see above). To identify more complex
gene regulatory mechanisms, the enrichment of transcription factor
binding sites (TFBS) among the shared signiﬁcantly altered genes in
PD/aging and all signiﬁcant genes in PD was assessed using the
F-Match algorithm (BioBase Explain 3.0 software, (Kel et al., 2006),
see Tables S7 and S8). In both analyses, a binding site targeted by
the transcription factor FOXO4was top-ranked among the signiﬁcant
results. FOXO4 is also signiﬁcantly up-regulated in the PDmeta-analysis
(Z-score 5.4) and known to up-regulate superoxide dismutase-2 in
response to oxidative stress (Araujo et al., 2011). A further signiﬁ-
cant TFBS in both analyses is targeted by PATZ1, a gene signiﬁcantly
up-regulated in PD (Z-score 3.4) previously found to inhibit endo-
thelial cell senescence and to be involved in the regulation of reac-
tive oxygen species levels (Cho et al., 2011). Additional experimental
studies will be required to conﬁrm the involvement of these regulatory
genes in PD.
In summary, the main functional annotations represented among
the 120 jointly deregulated genes in PD and aging point to shared alter-
ations in cellular processes that have previously been implicated in the
disease and in particular the early stages of PD pathogenesis. Aging-
related activity changes in these processes and upstream transcription
factors may therefore contribute to the age-dependence of PD risk,
and someof themost robust among these changes (e.g., the pronounced
up-regulation of several metallothioneins) for genes which are also
expressed in peripheral tissues could serve as a basis for developing
multifactorial biomarker models.
Jointly deregulated pathways and network modules in Parkinson's disease
and brain aging
To obtain a pathway-level statistical assessment of shared tran-
scriptome changes in aging and PD, we use a network-based pathway
analysis approach,which also enables a visual analysis of the underlying
network for top-ranked associations between known cellular pathways
and differentially expressed genes. As a complement to a classical path-
way enrichment analysis (scoring the signiﬁcance of the overlap
between members of cellular pathways and deregulated genes from
a microarray study), network-based association statistics can identify
new signiﬁcant interrelations between gene/protein sets with
small or no overlap. For this purpose, a statistical test assesses
whether the mapped gene/protein sets are more densely and closely
interconnected in a protein–protein interaction network or gene
regulatory network than expected by chance according to a random
background model (see Methods). Thus, for the pathway-level anal-
ysis of PD/aging transcriptome alterations, we mapped all signiﬁ-
cantly differentially expressed genes (FDR b 0.05) from the aging
data set and the matched-size top-ranked genes from the PD cross-
study analysis (again with FDR b 0.05) onto a genome-scale pro-
tein–protein interaction network, containing only experimentally
veriﬁed, direct physical interactions assembled from public databases
(Bossi and Lehner, nd.). Next, we scored the associations of themappedgenes with known cellular pathways from public databases (Gene
Ontology (Ashburner et al., 2000), KEGG (Kanehisa and Goto, 2000),
WikiPathways (Pico et al., 2008) and Reactome (Joshi-Tope et al.,
2005) using both a conventional enrichment analysis (Fisher's exact
test) and our previously developed graph-based statistic, implemented
in the public web-application EnrichNet (see Glaab et al., 2012 and
Methods for details).
Table 3 shows the biological processes from theGeneOntology (GO)
database which were identiﬁed to have statistically signiﬁcant over-
representation or network association scores with the deregulated
genes in PD and aging (network association was measured in terms
of the XD-score as deﬁned in Glaab et al., 2012, which assigns higher
scores to more signiﬁcant associations, and pathway over-
representation was measured using Fisher's exact test and q-value
false-discovery rate scores; see Supplementary Material for the results
on other pathway databases). The ﬁrst seven table entries contain the
processes signiﬁcant in terms of the network association score, and
the last entry (synaptic transmission process, GO:0007268) represents
the only process signiﬁcant in terms of the over-representation analysis
(q-value b 0.05).
Overall, 5 of the 8 GO biological processes scored to have signiﬁcant
associations with the aging- and PD-deregulated genes are synaptic
processes (synaptic vesicle endocytosis, positive regulation of synaptic
transmission, dopaminergic synaptic transmission, regulation of long-
term neuronal synaptic plasticity and general synaptic transmission), sug-
gesting that they belong to those most profoundly affected by PD- and
aging-related gene alterations. Among the other signiﬁcant pathways,
the top-ranked GO-term dopamine metabolic processmatches with the
known decline in dopamine synthesis observed during natural aging
and PD pathogenesis (see Introduction).Moreover, two of the identiﬁed
signiﬁcantGO-termspoint to associations of the deregulated geneswith
endocytic processes (positive regulation of endocytosis and synaptic
vesicle endocytosis). Since LRRK2, the most commonly mutated gene in
familial cases of PD, is known to regulate synaptic vesicle endocytosis
(Shin et al., 2008), and aggregation of α-synuclein as one of the major
neuropathological hallmarks of PD was found to be associated with
defects in endosomal trafﬁcking in a Saccharomyces cerevisiae model
for PD (Soper et al., 2011), these observations warrant further study of
endocytic pathway alterations as a functional link between aging and
PD (see also (Blanpied et al., 2003; Nixon, 2005) for a discussion of
age-related changes in endocytosis and endosome dysfunction in neu-
rodegenerative diseases).
An entirely novel association between brain aging processes and
molecular changes in PD is suggested by the signiﬁcant network associ-
ation of the deregulated genes with the GO-term phosphatidylinositol
metabolic process. This matches with an aging-related decline in the ac-
tivity of this pathway observed in rats and the known role of the phos-
phatidylinositol 3-kinase (PI3K)/Akt pathway in controlling the survival
of neurons (Chae and Kim, 2009).
To investigate the identiﬁed pathway associations in more detail,
we created visualizations of the sub-networks interlinking the aging/
PD-deregulated genes with the cellular processes. Figs. S10–S17 show
corresponding sub-networks for the top-rankedGO terms. These visual-
izations reveal, for example, that two interaction partners of the familial
PD-associated alpha-synuclein protein (SNCA) are signiﬁcantly altered
during adult aging, MAPT (see previous discussion above) and the
SNCA-degrading serine protease KLK6.
Apart from using generic pathway databases, we have mapped the
signiﬁcant genes in aging and PD onto a cellular process map speciﬁc
for Parkinson's disease and obtained from manual curation of the lit-
erature in collaboration with the Systems Biology Institute in Tokio,
Japan (Fujita et al., 2014). An interactive version of this map has
beenmade publicly available for online exploration, including differ-
ent color-overlays to highlight the deregulated genes in aging and PD
identiﬁed in our study (http://minerva.uni.lu/MapViewer/map?id=
pdmap-ageing).
Table 4
Genes containing PD-associated SNPswith signiﬁcant differential expression in both Parkinson's disease and adult brain aging (GWAS ﬁndingswith signiﬁcance p b 10E-08 are highlight-
ed in bold).
CorrelationDeregulation in PDGWASGeneGenesymbol
with agingsamples (Z–score)p–valuedescription(HGNC)
7E–12 –2.88 –0.51
6E–08 4.05 –0.41
4.2E–05 4.31 0.57
–4.2 –0.44
–4.99 –0.45
MAPT microtubule–associatedproteintau
PLEKHM1 pleckstrinhomologydomaincontaining,
familyMmember1
metallothionein1GMT1G
CAMTA1 calmodulinbindingtranscriptionactivator1 0.0001
FAM49A familywithsequencesimilarity49,memberA 0.0005
ARHGEF10 Rhoguaninenucleotideexchangefactor(GEF)10 0.0009 4.57 –0.25
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aging-/PD-deregulated genes
Apart from the contribution of aging to the risk of developing PD and
different environmental risk factors, thedisease is also thought to have a
major genetic component. Familial cases of PD with known causative
mutations currently account for only 5% to 10% of patients (Lesage and
Brice, 2009); however, the patients' family history and genome-wide
association studies (GWAS) suggest that a signiﬁcantly larger number
of genetic variations alters the disease risk (e.g., a recent large-scale
GWAS estimated the heritability of PD to be at least 0.27 Do et al.,
2011). As an additional exploratory analysis, we therefore investigated
a possible enrichment of genes with PD-associated sequence variants
from published GWAS reported in the Ensembl Variation database
(Chen et al., 2010) among the genes with signiﬁcantly altered expres-
sion in PD and aging (seeMethods section for details on data collection).
For this purpose, we assigned the SNPs to two groups depending on
their signiﬁcance: (1) SNPs with genome-wide signiﬁcance (deﬁned
as p b 10E-08) and (2) suggestive SNPs (deﬁned as p b 0.001).
From the set of 325 unique genes with suggestive PD-linked SNPs
obtained from the Ensembl database, we found 6 genes (2 among
them with genome-wide signiﬁcance) overlapping with the signiﬁ-
cantly altered genes in PD and aging (p = 0.03 for the overlap with
the suggestive set and p = 0.01 for the overlap with the genome-
wide signiﬁcant set; Fisher's exact test). These include the already
discussed genes tau (MAPT) and metallothionein 1G (MT1G), but
also four new candidate disease genes for further investigations:
FAM49A, ARHGEF10, CAMTA1 and PLEKHM1 (see Table 4, a detailed
discussion for each of these genes in the context of PD is provided in
the ﬁnal section of the Supplementary Material). Since the available
transcriptome data were not complemented by corresponding sequence
variant data for the same samples to assess a direct relation between ge-
nome and transcriptome alterations, veriﬁcation of the candidate genes
derived from this exploratory analysis will require validation on inde-
pendent complementary genetic and transcriptome data.
Conclusions
The joint analyses of brain gene expression in natural aging and PD
reveal signiﬁcant shared individual gene and cellular pathway alter-
ations. Apart from the observed changes in processes implicated in
aging and PD pathogenesis, including mitochondrial dysfunction,
disruption of lysosomal/autophagic function and apoptosis, neuro-
inﬂammation and metal ion homeostasis, we ﬁnd previously unreport-
ed signiﬁcant joint process alterations, e.g., affecting synaptic vesicle
endocytosis and phosphatidylinositol metabolism. Complementing the
identiﬁcation of signiﬁcant genes and pathways, subsequent network,
literature mining and knockdown data analyses for NR4A2 as the most
signiﬁcantly under-expressed gene in PD among the jointly alteredgenes also suggest a mechanistic explanation of how the down-
regulation of NR4A2 with increasing age may increase PD risk via re-
duced expression of dopamine transporters and mitochondrial genes
and an up-regulation of alpha-synuclein. These results match with the
dopamine-depleting effects observed in NR4A2 knockout mice and the
human PD-associated mutations reported in this gene.
Since aging is regarded as one of the main risk factors for PD, the
most robust gene and process deregulations among the shared signiﬁ-
cant alterations also provide speciﬁc candidates for building early stage
risk biomarker models for PD or general neurodegeneration. This task
will require further research and experimental validation and may be
achieved by screening for correlated surrogate markers in cerebrospinal
ﬂuid, blood or saliva.
Finally, the combined analysis approach for aging and PD proposed
here may serve as a template for applying similar integrative analyses
to other neurodegenerative diseases in order to study aging-related
commonalities between these disorders.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2014.11.002.
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